Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Former FDA Director: Pneumonia Standards May Be Tough To Follow In Real World R&D

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency's former microbials head Mark Goldberger highlights guidance flaws at ICAAC.
Advertisement

Related Content

Panel Gives Mixed Reviews To Using Single Trial For Community-Acquired Pneumonia
FDA Indicates Flexibility On Evidence To Support Efficacy In Pneumonia
FDA Indicates Flexibility On Evidence To Support Efficacy In Pneumonia
Would A Mortality Endpoint Be The Death Knell For Antibiotics Development?
Would A Mortality Endpoint Be The Death Knell For Antibiotics Development?
CAP Drugs Must Meet Stricter Noninferiority Criteria Under Draft FDA Guidance
FDA Updating Antibiotic Guidances, But Is It Too Late For Some Sponsors?

Topics

Advertisement
UsernamePublicRestriction

Register

PS069973

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel